![](https://webarchive.library.unt.edu/web/20081007141352im_/http://www.cancer.gov/images/spacer.gif) |
|
Phase II Randomized Pilot Chemoprevention Study of Celecoxib in Former Heavy Smokers At High Risk of Primary or Second Primary Lung Cancer
Alternate Title Basic Trial Information Objectives Entry Criteria Expected Enrollment Outcomes Outline Trial Contact Information Registry Information
Alternate Title
Celecoxib in Preventing Lung Cancer in Former Heavy Smokers
Basic Trial Information
![](https://webarchive.library.unt.edu/web/20081007141352im_/http://www.cancer.gov/images/spacer.gif) |
Phase
![](https://webarchive.library.unt.edu/web/20081007141352im_/http://www.cancer.gov/images/spacer.gif) |
![](https://webarchive.library.unt.edu/web/20081007141352im_/http://www.cancer.gov/images/spacer.gif) |
![](https://webarchive.library.unt.edu/web/20081007141352im_/http://www.cancer.gov/images/spacer.gif) |
![](https://webarchive.library.unt.edu/web/20081007141352im_/http://www.cancer.gov/images/spacer.gif) |
Type
![](https://webarchive.library.unt.edu/web/20081007141352im_/http://www.cancer.gov/images/spacer.gif) |
![](https://webarchive.library.unt.edu/web/20081007141352im_/http://www.cancer.gov/images/spacer.gif) |
![](https://webarchive.library.unt.edu/web/20081007141352im_/http://www.cancer.gov/images/spacer.gif) |
![](https://webarchive.library.unt.edu/web/20081007141352im_/http://www.cancer.gov/images/spacer.gif) |
Status
![](https://webarchive.library.unt.edu/web/20081007141352im_/http://www.cancer.gov/images/spacer.gif) |
![](https://webarchive.library.unt.edu/web/20081007141352im_/http://www.cancer.gov/images/spacer.gif) |
![](https://webarchive.library.unt.edu/web/20081007141352im_/http://www.cancer.gov/images/spacer.gif) |
![](https://webarchive.library.unt.edu/web/20081007141352im_/http://www.cancer.gov/images/spacer.gif) |
Age
![](https://webarchive.library.unt.edu/web/20081007141352im_/http://www.cancer.gov/images/spacer.gif) |
![](https://webarchive.library.unt.edu/web/20081007141352im_/http://www.cancer.gov/images/spacer.gif) |
![](https://webarchive.library.unt.edu/web/20081007141352im_/http://www.cancer.gov/images/spacer.gif) |
![](https://webarchive.library.unt.edu/web/20081007141352im_/http://www.cancer.gov/images/spacer.gif) |
Sponsor
![](https://webarchive.library.unt.edu/web/20081007141352im_/http://www.cancer.gov/images/spacer.gif) |
![](https://webarchive.library.unt.edu/web/20081007141352im_/http://www.cancer.gov/images/spacer.gif) |
![](https://webarchive.library.unt.edu/web/20081007141352im_/http://www.cancer.gov/images/spacer.gif) |
![](https://webarchive.library.unt.edu/web/20081007141352im_/http://www.cancer.gov/images/spacer.gif) |
Protocol IDs
![](https://webarchive.library.unt.edu/web/20081007141352im_/http://www.cancer.gov/images/spacer.gif) |
![](https://webarchive.library.unt.edu/web/20081007141352im_/http://www.cancer.gov/images/spacer.gif) |
![](https://webarchive.library.unt.edu/web/20081007141352im_/http://www.cancer.gov/images/spacer.gif) |
![](https://webarchive.library.unt.edu/web/20081007141352im_/http://www.cancer.gov/images/spacer.gif) |
![](https://webarchive.library.unt.edu/web/20081007141352im_/http://www.cancer.gov/images/spacer.gif)
Phase II
![](https://webarchive.library.unt.edu/web/20081007141352im_/http://www.cancer.gov/images/spacer.gif)
|
![](https://webarchive.library.unt.edu/web/20081007141352im_/http://www.cancer.gov/images/spacer.gif) |
![](https://webarchive.library.unt.edu/web/20081007141352im_/http://www.cancer.gov/images/spacer.gif) |
![](https://webarchive.library.unt.edu/web/20081007141352im_/http://www.cancer.gov/images/spacer.gif) |
![](https://webarchive.library.unt.edu/web/20081007141352im_/http://www.cancer.gov/images/spacer.gif)
Prevention
![](https://webarchive.library.unt.edu/web/20081007141352im_/http://www.cancer.gov/images/spacer.gif)
|
![](https://webarchive.library.unt.edu/web/20081007141352im_/http://www.cancer.gov/images/spacer.gif) |
![](https://webarchive.library.unt.edu/web/20081007141352im_/http://www.cancer.gov/images/spacer.gif) |
![](https://webarchive.library.unt.edu/web/20081007141352im_/http://www.cancer.gov/images/spacer.gif) |
![](https://webarchive.library.unt.edu/web/20081007141352im_/http://www.cancer.gov/images/spacer.gif)
Active
![](https://webarchive.library.unt.edu/web/20081007141352im_/http://www.cancer.gov/images/spacer.gif)
|
![](https://webarchive.library.unt.edu/web/20081007141352im_/http://www.cancer.gov/images/spacer.gif) |
![](https://webarchive.library.unt.edu/web/20081007141352im_/http://www.cancer.gov/images/spacer.gif) |
![](https://webarchive.library.unt.edu/web/20081007141352im_/http://www.cancer.gov/images/spacer.gif) |
![](https://webarchive.library.unt.edu/web/20081007141352im_/http://www.cancer.gov/images/spacer.gif)
45 and over
![](https://webarchive.library.unt.edu/web/20081007141352im_/http://www.cancer.gov/images/spacer.gif)
|
![](https://webarchive.library.unt.edu/web/20081007141352im_/http://www.cancer.gov/images/spacer.gif) |
![](https://webarchive.library.unt.edu/web/20081007141352im_/http://www.cancer.gov/images/spacer.gif) |
![](https://webarchive.library.unt.edu/web/20081007141352im_/http://www.cancer.gov/images/spacer.gif) |
![](https://webarchive.library.unt.edu/web/20081007141352im_/http://www.cancer.gov/images/spacer.gif)
NCI
![](https://webarchive.library.unt.edu/web/20081007141352im_/http://www.cancer.gov/images/spacer.gif)
|
![](https://webarchive.library.unt.edu/web/20081007141352im_/http://www.cancer.gov/images/spacer.gif) |
![](https://webarchive.library.unt.edu/web/20081007141352im_/http://www.cancer.gov/images/spacer.gif) |
![](https://webarchive.library.unt.edu/web/20081007141352im_/http://www.cancer.gov/images/spacer.gif) |
![](https://webarchive.library.unt.edu/web/20081007141352im_/http://www.cancer.gov/images/spacer.gif)
UCLA-0108074 NCT00055978
![](https://webarchive.library.unt.edu/web/20081007141352im_/http://www.cancer.gov/images/spacer.gif)
|
![](https://webarchive.library.unt.edu/web/20081007141352im_/http://www.cancer.gov/images/spacer.gif) |
|
Objectives - Determine the feasibility of chemoprevention of lung cancer with celecoxib in former heavy smokers at risk for developing primary or second primary lung cancer.
- Determine the safety and side effects of this drug in these patients.
- Determine the quality of life of patients treated with this drug.
- Determine the role of COX-2-specific inhibitors (e.g., celecoxib) on antitumor immunity within the lung microenvironment of these patients.
- Determine the effects of COX-2 inhibition on angiogenesis in these patients.
Entry Criteria Disease Characteristics:
- Former heavy smoker meeting 1 of the following high-risk criteria for lung cancer:
- 30 pack years
- Histologically confirmed stage I non-small cell lung cancer (NSCLC) that was curatively treated at least 6 months ago, with no evidence of recurrence or second primary tumor, and smoked for at least 10 pack years
- Quit smoking at least 1 year ago
Prior/Concurrent Therapy:
Biologic therapy Chemotherapy - No prior cytotoxic chemotherapy
Endocrine therapy - No concurrent systemic corticosteroids
Radiotherapy - No prior radiotherapy to the chest
Surgery - See Disease Characteristics
Other - More than 3 months since prior chemopreventive drugs (e.g., retinoids)
- More than 3 weeks since prior NSAIDs
- More than 3 months since prior photosensitizing agents (e.g., hematoporphyrin derivative)
- No concurrent NSAIDs (except baby aspirin)
- No concurrent warfarin
- No concurrent medications known to alter or be affected by the alteration of hepatic enzyme p450 2C9 (e.g., fluconazole)
Patient Characteristics:
Age Performance status Life expectancy Hematopoietic - Blood chemistry and cell counts normal
Hepatic - No history of cirrhosis
- No liver dysfunction
- ALT/AST normal
- Alkaline phosphatase normal
- Lactic dehydrogenase normal
- No coagulopathy
Renal - No renal dysfunction
- BUN normal
- Creatinine normal
Cardiovascular - No history of significant coronary artery disease
- No unstable angina
Pulmonary - No end-stage respiratory disease
Other - Not pregnant or nursing
- Negative pregnancy test
- Fertile patients must use effective contraception
- No prior gastrointestinal ulceration, bleeding, or perforation
- No other malignancy within the past 5 years except nonmelanoma skin cancer or carcinoma in situ of the cervix
- No known hypersensitivity to celecoxib, sulfonamides, aspirin, or other non-steroidal anti-inflammatory drugs (NSAIDs)
- No other concurrent medical condition that would preclude study participation
Expected Enrollment 180A total of 180 patients (90 per treatment arm) will be accrued for this study. Outcomes Primary Outcome(s)Modulation of the ki-67 labeling index Phenotypic modulation of the bronchial histology
Secondary Outcome(s)Evidence of molecular/genetic aberrations Changes indicative of response to treatment in the targeted signaling pathway Parameters that reflect the overall balance of the epigenetic phenomenon thought to facilitate or promote tumorigenesis
Outline This is a randomized, double-blind, placebo-controlled study. Patients are stratified according to presence of preinvasive lesions (yes vs no). Patients are randomized to 1 of 2 treatment arms. - Arm I: Patients receive oral placebo twice daily for 6 months followed by oral celecoxib twice daily for 6 months.
- Arm II: Patients receive oral celecoxib twice daily for 6 months followed by oral placebo twice daily for 6 months.
Treatment in both arms continues in the absence of disease progression or unacceptable toxicity. Quality of life is assessed every 6 months during treatment and then annually for up to 4 years. Patients are followed annually for up to 4 years.
Trial Contact Information
Trial Lead Organizations Jonsson Comprehensive Cancer Center at UCLA ![](https://webarchive.library.unt.edu/web/20081007141352im_/http://www.cancer.gov/images/spacer.gif) | ![](https://webarchive.library.unt.edu/web/20081007141352im_/http://www.cancer.gov/images/spacer.gif) | ![](https://webarchive.library.unt.edu/web/20081007141352im_/http://www.cancer.gov/images/spacer.gif) | Jenny Mao, MD, Protocol chair | ![](https://webarchive.library.unt.edu/web/20081007141352im_/http://www.cancer.gov/images/spacer.gif) | Ph: 310-825-3100; 888-798-0719 |
| ![](https://webarchive.library.unt.edu/web/20081007141352im_/http://www.cancer.gov/images/spacer.gif) | Trial Sites
![](https://webarchive.library.unt.edu/web/20081007141352im_/http://www.cancer.gov/images/spacer.gif) |
![](https://webarchive.library.unt.edu/web/20081007141352im_/http://www.cancer.gov/images/spacer.gif) |
![](https://webarchive.library.unt.edu/web/20081007141352im_/http://www.cancer.gov/images/spacer.gif) |
![](https://webarchive.library.unt.edu/web/20081007141352im_/http://www.cancer.gov/images/spacer.gif) |
U.S.A. |
![](https://webarchive.library.unt.edu/web/20081007141352im_/http://www.cancer.gov/images/spacer.gif) |
California |
![](https://webarchive.library.unt.edu/web/20081007141352im_/http://www.cancer.gov/images/spacer.gif) |
|
Los Angeles |
![](https://webarchive.library.unt.edu/web/20081007141352im_/http://www.cancer.gov/images/spacer.gif) |
| | | | | | | | Jonsson Comprehensive Cancer Center at UCLA |
| | Clinical Trials Office - Jonsson Comprehensive Cancer Center at UCLA | |
|
Registry Information | ![](https://webarchive.library.unt.edu/web/20081007141352im_/http://www.cancer.gov/images/spacer.gif) | Official Title | | Lung Cancer Chemoprevention With Celecoxib In Ex-Smokers | ![](https://webarchive.library.unt.edu/web/20081007141352im_/http://www.cancer.gov/images/spacer.gif) | Trial Start Date | | 2002-10-17 | ![](https://webarchive.library.unt.edu/web/20081007141352im_/http://www.cancer.gov/images/spacer.gif) | Registered in ClinicalTrials.gov | | NCT00055978 | ![](https://webarchive.library.unt.edu/web/20081007141352im_/http://www.cancer.gov/images/spacer.gif) | Date Submitted to PDQ | | 2003-01-28 | ![](https://webarchive.library.unt.edu/web/20081007141352im_/http://www.cancer.gov/images/spacer.gif) | Information Last Verified | | 2007-06-03 | ![](https://webarchive.library.unt.edu/web/20081007141352im_/http://www.cancer.gov/images/spacer.gif) | NCI Grant/Contract Number | | CA16042, CA096134 |
Note: The purpose of most clinical trials listed in this database is to test new cancer treatments, or new methods of diagnosing, screening, or preventing cancer. Because all potentially harmful side effects are not known before a trial is conducted, dose and schedule modifications may be required for participants if they develop side effects from the treatment or test. The therapy or test described in this clinical trial is intended for use by clinical oncologists in carefully structured settings, and may not prove to be more effective than standard treatment. A responsible investigator associated with this clinical trial should be consulted before using this protocol. Back to Top |
![](images/spacer.gif) |